Who is the CEO of Metabiomed?

According to the DART company overview, Metabiomed's representative director is 오석송 (name as registered in Korean). The company was founded on 1999-07-01.

Where is Metabiomed listed?

Metabiomed trades on the Korea Exchange KOSDAQ market under the ticker 059210. Its fiscal year ends in December.

Does Metabiomed pay a dividend?

Yes. For fiscal 2025, Metabiomed paid a cash dividend of ₩105 per common share, a 2.1% yield as stated in its annual report, with a payout ratio of 25.9%. The prior year's dividend was ₩30.

Does Metabiomed have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Op. margin 20%+ (operating margin of 20% or more on quarterly revenue of at least ₩5bn); Dividend grower (dividend per share raised three years in a row); Insider buying (officers or major shareholders reported adding shares (30 days)). These are factual flags, not investment advice.

Which companies are in the same industry as Metabiomed?

Under the Korean Standard Industrial Classification recorded on DART, Metabiomed is grouped with 31 other listed companies in medical supplies. The most covered in Korean news over the past 30 days are HLB, PharmaResearch and Rokit Healthcare.

Metabiomed KRX:059210KOSDAQ

메타바이오메드 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days0

DART filings, 7 days0

Articles tracked10since Sep 11

In Q2 2026, Metabiomed reported revenue of ₩27.0bn, up 6.0% year on year, and operating profit of ₩6.3bn. Metabiomed (메타바이오메드) appeared in 0 Korean news articles and 0 DART filings over the past seven days.

Filing signals Op. margin 20%+ Dividend grower Insider buying Screener

Metabiomed quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩27.0bn	+6.0%	₩6.3bn margin 23.2%	₩6.3bn
Q1 2026	₩24.4bn	-11.8%	₩4.9bn margin 19.9%	₩4.4bn
Q4 2025 derived	₩26.2bn	+13.8%	₩2.9bn margin 11.2%	₩1.6bn
Q3 2025	₩23.5bn	+1.7%	₩5.1bn margin 21.6%	₩4.5bn
Q2 2025	₩25.5bn	+0.6%	₩7.8bn margin 30.6%	−₩884m
Q1 2025	₩27.7bn	+23.1%	₩5.6bn margin 20.3%	₩5.6bn
Q4 2024 derived	₩23.1bn	+8.1%	₩4.8bn margin 21.0%	₩9.0bn
Q3 2024	₩23.1bn	+10.6%	₩3.8bn margin 16.6%	₩3.7bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Metabiomed top stories 2 weeks, by number of outlets

No story covered by multiple outlets in the past two weeks.

Latest Metabiomed news Korean headlines

Oct 1312:59

메타바이오메드, 29억 원 규모 AI 전환 추진…바이오폴리머 공정 최적화
바이오타임즈
Oct 1310:53

메타바이오메드, 29억원 규모 국책사업 협약 기염
파이낸셜포스트
Oct 1310:04

메타바이오메드, 29억원 들여 의료용 소재 제조공정 AI 전환
중부매일
Oct 1308:08
메타바이오메드, 29억 규모 정부 '상생형 AX' 사업 협약
아시아경제
3 more on this story · 3 outlets
- 메타바이오메드, 29억 규모 정부 '상생형 AX' 사업 협약컨슈머타임스 · Oct 13 08:36
- 메타바이오메드, 29억원 규모 '상생형 AX' 협약뉴스핌 · Oct 13 09:48
- 메타바이오메드, 정부 '상생형 AX' 사업 협약한국경제TV · Oct 13 14:59
Sep 1709:56

Major메타바이오메드·솔메딕스 맞손…생분해성 의료기기 공동개발 나선다
메디컬투데이Partnership
Sep 1709:20

메타바이오메드, '솔메딕스'와 생분해성 의료기기 시장 공략
팍스경제TV
Sep 1708:50

메타바이오메드, 솔메딕스와 제휴해 생분해성 의료기기 개발
뉴스핌

Articles per day 2 weeks

Company profile

CEO: 오석송
Industry: Medical supplies
Founded: 1999-07-01
Fiscal year-end: December
Head office: 충청북도 청주시
Website: wwwlmeta-biomed.com
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Metabiomed dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩105	2.1%	25.9%
FY2024	₩30	0.8%	3.1%
FY2023	₩20	0.5%	4.5%

Raised 3 years in a row

Same industry Medical supplies

All in industry

Company	Latest quarter op. profit	Articles 30d
HLB	−₩22.5bn	313
PharmaResearch	₩66.5bn	129
Rokit Healthcare	−₩13.5bn	79
Seegene	₩21.6bn	41
Jetema	₩2.3bn	26
AbClon	−₩6.3bn	24
SCL Science	₩406m	21
Asta	−₩839m	16

Compare Metabiomed side by side with these companies

Metabiomed DART filings

Oct 216:23

Insider ownership report 임원ㆍ주요주주특정증권등소유상황보고서
Ownership reports
Sep 1415:36

Investor relations event 기업설명회(IR)개최
Other

Mentioned alongside 2 weeks

No co-mentioned companies yet.

Metabiomed FAQ

Who is the CEO of Metabiomed?: According to the DART company overview, Metabiomed's representative director is 오석송 (name as registered in Korean). The company was founded on 1999-07-01.
Where is Metabiomed listed?: Metabiomed trades on the Korea Exchange KOSDAQ market under the ticker 059210. Its fiscal year ends in December.
What were Metabiomed's latest quarterly results?: In Q2 2026, Metabiomed reported revenue of ₩27.0bn, up 6.0% year on year, and operating profit of ₩6.3bn. Figures come from reports filed on DART.
Does Metabiomed pay a dividend?: Yes. For fiscal 2025, Metabiomed paid a cash dividend of ₩105 per common share, a 2.1% yield as stated in its annual report, with a payout ratio of 25.9%. The prior year's dividend was ₩30.
Does Metabiomed have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Op. margin 20%+ (operating margin of 20% or more on quarterly revenue of at least ₩5bn); Dividend grower (dividend per share raised three years in a row); Insider buying (officers or major shareholders reported adding shares (30 days)). These are factual flags, not investment advice.
Which companies are in the same industry as Metabiomed?: Under the Korean Standard Industrial Classification recorded on DART, Metabiomed is grouped with 31 other listed companies in medical supplies. The most covered in Korean news over the past 30 days are HLB, PharmaResearch and Rokit Healthcare.